Introduction
Factor XIII (FXIII) is the final enzyme in the coagulation cascade and it plays a key role in maintaining the functional integrity of fibrin clots. This coagulation factor circulates in plasma as a protransglutaminase that consists of two catalytic A subunits and two carrier/protective B subunits (1, 2) . The A subunits contain the catalytic component, activation peptide and the substraterecognition regions of FXIII; they are found bound to B subunits in plasma or alone as intracellular homodimers (2, 3) .
FXIII is activated by thrombin (factor IIa) to form a transglutaminase that catalyses covalent bond formation between the -carboxyamine group of a glutamine residue and the -amino group of a lysine residue. During clot formation, stability is achieved through covalent cross-linking of fibrin -and -chains and covalent binding of antifibrinolytic proteins to fibrin (2, 4) . The critical function of FXIII in haemostasis is reflected in the broad spectrum of bleeding complications that is observed in patients with congenital FXIII deficiency, a rare autosomal recessive trait (5) . Patients often suffer from umbilical stump bleeding, subcutaneous bleeding, muscle haemorrhage, postoperative haemorrhage, and potentially fatal intracranial haemorrhage, the latter occurring in approximately one-third (34%) of patients (5) . Among rare bleeding disorders, FXIII deficiency is associated with the highest proportion of severe bleeding episodes, underscoring the importance of this coagulation factor in normal haemostasis (6) . Another clinical feature in patients with congenital FXIII deficiency is poor and slow wound healing (7) . FXIII deficiency is not identified by standard coagulation testing, and the lack of a readily available and accurate test for the condition hampers diagnosis, particularly in less severe cases (4) . FXIII concentrate (human) is recommended as prophylactic treatment for patients with congenital FXIII deficiency (8) .
While the 'classic' substrates for FXIII are the non-cross-linked fibrin polymers and, potentially, fibrinogen (9) , other biologically important molecules have been shown to be substrates as well (10) .
Antifibrinolytic proteins such as 2-antiplasmin, thrombin-activatable fibrinolysis inhibitor (TAFI) and 2-macroglobulin are also incorporated into the clot, with cross-linking of 2-antiplasmin to fibrin being the principal mechanism whereby plasmin-mediated degradation of the fibrin clot is minimised (10) . Furthermore, macromolecular components of plasma and the extracellular matrix, e.g. fibronectin and vitronectin are also cross-linked to fibrin, influencing the behaviour of fibroblasts, neutrophils and leukocytes through integrin signalling properties (10) .
An increasing body of evidence indicates that FXIII is a multifunctional protein that, beyond a role in haemostasis, plays an important part in a wide range of other physiological and pathological Page 5 processes, including tissue repair and wound healing. The aim of this review article is to provide an overview of these diverse functions of FXIII and to highlight the potential for clinical use of FXIII replacement therapy in a range of conditions beyond congenital FXIII deficiency.
Perioperative bleeding
Adequate levels of FXIII are required in patients undergoing surgery to prevent or manage perioperative bleeding. In a study of 226 consecutive patients who underwent elective surgery, parameters relating to the final steps of coagulation were compared in those with unexplained intraoperative bleeding (defined according to prespecified clinical criteria) versus those with no such bleeding (11) . Patients included in the study underwent different types of surgery in the departments of general surgery, neurosurgery, orthopaedics and urology. In total, 8.8% of the cohort developed "unexplained" (at the time) bleeding and, compared with "non-bleeders", these patients had significantly lower levels of FXIII activity during and after surgery. These findings were paralleled by significantly lower availability of FXIII per unit thrombin generated and early loss of clot firmness of the whole blood clot, as assessed by the thromboelastometry (ROTEM) NATEM test, at all time points for "bleeders" versus "non-bleeders". Of note, reduced clot firmness was detected at a time point when increased blood loss was not yet apparent, leading to the suggestion that early administration of FXIII may be beneficial in patients at risk of perioperative bleeding. In fact, this approach was subsequently evaluated prospectively in a randomised, placebo-controlled trial and found to be beneficial (see below) (12) .
Inadequate levels of FXIII activity have been associated with an increased risk of postoperative haemorrhage. In a retrospective study of 1264 patients who underwent intracranial surgery, postoperative FXIII activity levels were measured in patients in whom coagulopathy was suspected despite normal results from standard coagulation monitoring (13) . Of 34 such patients, 8 were found to have FXIII deficiency postoperatively, and all of these patients suffered a major postoperative haemorrhage. In contrast, only three of the 26 patients with suspected coagulopathy and normal FXIII activity levels experienced a postoperative haemorrhage, a difference that was statistically significant (p<0.00001). A likely explanation for these phenomena is the fact that reduction of available FXIII activity is associated with reduced clot firmness as well as a decreased resistance of the clot to fibrinolysis (14, 15).
Clinical trial data Page 6 While these retrospectively collected clinical or in vitro data do not demonstrate causality between low FXIII activity levels and perioperative haemorrhage, this putative relationship is supported by data from randomised, placebo-controlled clinical trials of FXIII supplementation. In a proof-ofconcept trial in elective gastrointestinal cancer surgery, loss of maximum clot firmness was significantly attenuated when FXIII concentrate (30 international unit [IU]/kg) a was administered early during surgery (p=0.004 versus placebo, Figure 1A ) in patients at risk (12) . Significant reductions in the secondary endpoints of blood loss ( Figure 1B ) and fibrinogen consumption ( Figure   1C ) were also observed following FXIII concentrate administration (12) . In a randomised, placebo- 
Case reports
A clinical utility of FXIII supplementation to manage bleeding in patients undergoing surgery has also been suggested by a number of case reports. For example, a patient with clopidogrel-related refractory bleeding following coronary artery bypass graft surgery was reported to have benefitted from the use of FXIII concentrate plus fibrinogen concentrate, after the administration of packed red blood cells, fresh frozen plasma, platelet concentrate, high-dose aprotinin, desmopressin, and recombinant activated factor VII had failed to stop the bleeding (17) .
In another patient requiring major abdominal intervention for liver rupture, addition of FXIII concentrate for the correction of repeatedly occurring low preoperative FXIII activity (50%) pre-, intra-and perioperatively led to normalisation of FXIII activity and to the interruption of secondary bleeding because of low FXIII activity; this case provides evidence and insight into the fact that the half-life of FXIII is dramatically shortened during a state of high consumption. The subsequent postoperative course was uneventful in this patient (18) .
In the same article, the authors describe a third patient who received a massive transfusion during emergency surgical treatment for multiple traumatic injuries. The resulting FXIII deficiency was Page 7 treated by administration of FXIII concentrate. Additional FXIII concentrate administration was used to address the ensuing generalised inflammation, sepsis and disseminated intravascular coagulation with bleeding, guided by timely measurements of FXIII activity (18) . 
Angiogenesis and the role of thrombospondin
There are multiple lines of evidence to suggest that the impaired wound healing seen in patients with congenital FXIII deficiency stems, at least in part, from the proangiogenic properties of FXIII.
More than a decade ago, it was reported that endothelial cells adhere to activated FXIII (FXIIIa) in an integrin-dependent manner (23, 24) . In vivo models also provide evidence for the proangiogenic effects of FXIIIa. In a neonatal heterotopic mouse heart allograft model, injection of thrombin-activated FXIII into the grafted tissue produced significantly more new vessels and significantly higher contractile performance compared with saline-injected graft tissue (26). In FXIII-knockout mice, the formation of new vessels into a subcutaneously injected Matrigel plug (a mixture that resembles the complex extracellular environment found in many tissues) was significantly decreased compared with control mice. This effect could be almost completely reversed by the addition of FXIIIa to the gel (26). In rats, addition of FXIII concentrate to a tibial defect filled with a biodegradable hydroxyapatite implant has been shown to stimulate in-growth of microvessels into the biomaterial. In contrast, in defects filled with hydroxyapatite alone, formation of capillaries was limited to the host bonehydroxyapatite surface (27) .
The inhibitory effect of FXIIIa on TSP-1 expression observed in in vitro and in vivo studies provides an insight into the mechanism by which this coagulation factor promotes angiogenesis. TSP-1 is one of the best characterised antiangiogenic factors (28) and has been shown to induce endothelial cell apoptosis and inhibit neovascularisation in sponge implants in mice with severe combined immunodeficiency. This is mediated through increased expression of the proapoptotic protein Bax, decreased expression of the antiapoptotic protein Bcl-2, and activation of the caspase cell-death pathway through processing of caspase-3 into smaller proapoptotic forms (29) .
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The importance of TSP-1 in angiogenesis is demonstrated by additional animal studies. In transgenic mice, targeted overexpression of TSP-1 in the skin was associated with potent inhibition of cutaneous tissue repair, granulation tissue formation and wound angiogenesis (30) . The observation that TSP-1 was not associated with major alterations in cutaneous vascular architecture or microvascular permeability suggests that chronic overexpression of TSP-1 in the skin preferentially affects wound-healing-associated angiogenesis rather than the angiogenesis associated with normal development and skin homeostasis. In a rabbit model of corneal neovascularisation, FXIIIa administration resulted in blood-vessel formation that was visible 48 hours after injection, whereas no such effect was observed following injection of saline into control eyes. Immunohistochemical analysis revealed that neovascularisation was accompanied by almost complete disappearance of TSP-1 in the cornea (25) .
Molecular studies in human umbilical vein endothelial cells (HUVECs) have elucidated some of the processes whereby the proangiogenic effect of FXIIIa is mediated (31) . Co-immunoprecipitation analysis demonstrated that FXIIIa cross-links v3 integrin with vascular endothelial growth factor receptor 2 (VEGFR-2) and enhances non-covalent binding between these two receptors. 
Clinical trial data
Several preliminary studies have demonstrated a possible positive effect of FXIII concentrate treatment in patients with systemic sclerosis ( 
Bacterial infections and wound healing Bacterial infections
There is convincing evidence that FXIII plays an important role in host defence against invasive bacteria (50) (51) (52) . In normal plasma, the induction of coagulation by Streptococcus pyogenes results in immobilisation of bacterial cells within the clot, with transmission electron microscopy revealing that the cells are cross-linked to fibrin fibres at multiple interaction sites (53) . This bacterial entrapment within the plasma clot was shown to be FXIII-dependent; cross-linking was not observed when FXIIIdeficient plasma was used. Immunostaining with a gold-labelled antibody against N---glutamyllysine elucidated further the nature of the interaction, revealing covalent interaction between one terminal of streptococcal M1 surface protein and a globular domain of fibrinogen (Figure 3 ) (53).
In a model of streptococcal skin infection, wild-type mice developed signs of tissue damage and severe pathological inflammation at the site of infection. When bacterial load was determined in blood, spleen and liver in these animals, colonisation was found to be significantly decreased by FXIII concentrate injection compared with non-treated controls (data for blood presented in Figure 4 ) (53 The involvement of FXIII in innate immunity extends to proteins of the complement system.
Functional proteomics data show that complement C3, the central component of the complement system, is a novel component of plasma clots and has an antifibrinolytic action (59) . Other data show that complement C3 is a substrate for FXIIIa, and that incorporation of this protein into clots occurs by covalent cross-linking by FXIIIa (60, 61) . In a further demonstration of the interaction between FXIII and the complement system, it has been shown that mannan-binding lectin-associated serine protease-1 (MASP-1) of the complement lectin pathway activates FXIII and is involved in fibrin clot formation (62) .
FXIII also interacts with cells of the immune system (reviewed by Bagoly et al.) (63) , being activated by human neutrophil elastase and downregulated by granulocyte proteases. Furthermore, FXIIIa enhances monocyte proliferation and migration, and inhibits monocyte apoptosis (64) . Although some investigators have suggested that monocytes and macrophages are a source of plasma FXIIIa,
arising from a non-classical secretory pathway (63, 65) , this has not been shown unequivocally.
Within the context of infectious disease conditions, FXIII has been implicated in the entrapment of various bacteria, and has been shown to interact with components of the immune system. This Page 13 aspect of the physiological role of FXIII certainly warrants more examination, as does any potential benefit for FXIII supplementation for the treatment of bacterial infections.
Wound healing
Impaired wound healing was noted in the original description of a patient with congenital FXIII deficiency (7), and subsequent reports have documented that up to 29% of those with severe congenital FXIII deficiency exhibit poor wound healing (5, 66, 67) . The multiple FXIII-dependent processes that are involved in wound healing are depicted in Figure 5 (52).
A key role for FXIII in wound healing has been demonstrated in FXIII-deficient transgenic mice, where healing of an excisional wound was markedly delayed compared with healing in normal mice or in FXIII -/-mice receiving FXIII supplementation (68). Impaired healing was accompanied by cellular and tissue defects, and these were also corrected by FXIII supplementation. A role for FXIII in wound healing has also been demonstrated in a rat burn model in which FXIII deficiency was induced by treatment with CCl4 (which caused hepatic injury) (69) , and in a bone-healing model in sheep (70) .
Another relevant mechanism for altered wound healing in FXIII deficiency is through interaction with TSP-1 and TGF- activation as discussed above in relation to the pathogenesis of systemic sclerosis.
Clinical trial data in leg-ulcer patients
An early study in patients with leg ulcers noted decreased FXIII activity in patients with either postphlebitic syndromes, post-phlebitic ulcers, varicose leg ulcer or mixed leg ulcers compared with those without venous disease (71) . Subsequent clinical evaluations of topical treatment of venous leg ulcers with FXIII have shown promising results in small case studies and trials (72) (73) (74) (75) . In a randomised, double-blind, placebo-controlled trial in 30 patients with chronic venous leg ulcers, topical application of FXIII concentrate was shown to produce a significant reduction in ulcer size compared with placebo, and this was accompanied by a significant reduction in fibrinolytic activity in tissue samples (75) . In another placebo-controlled trial of 24 patients, a significantly greater daily reduction in ulcer size was observed in FXIII concentrate-treated patients with small leg ulcers (<1000 mm 2 ) relative to those with larger ulcers (>1000 mm 2 ) (p<0.015), although there was no significant difference between treated patients and controls (74) . Interestingly, genotype/phenotype studies in humans have shown that the FXIII V34L polymorphism affects chronic venous leg ulcer size, healing time and response to superficial venous surgery, with healing time after superficial venous surgery increased in FXIII 34V homozygotes and ulcer size inversely related to the number of FXIII 34L alleles (76) . This is biologically plausible because the FXIII 34L variant is associated with a faster rate of transglutaminase activation compared with the FXIII 34V variant (77, 78) , an effect that Page 14 could be predicted to strengthen the extracellular matrix, and increase fibroblast migration/proliferation, and angiogenesis (earlier reports of increased transglutaminase activity (79) may have been observed due to incomplete thrombin activation but were later disproven (78)).
These studies indicate that FXIII may play an important role in the healing of leg ulcers. However, they do have some limiting features, such as the low patient numbers and, while two of the studies were placebo-controlled (74, 75) , future larger, controlled clinical trials are required to determine the therapeutic potential of FXIII administration for wound healing of venous leg ulcers.
Wound healing after myocardial infarction
Experimental evidence from transgenic mice indicates that FXIII has a role in wound healing after myocardial infarction (MI) (80) . 
Future perspectives
In addition to its presence in plasma, FXIII-A can also be found in various cells including platelets, monocytes, macrophages, chondrocytes, osteoblasts and osteoclasts (as reviewed by Muszbeck 2011 (83)). There is evidence to support a role for cellular FXIII-A in several processes, including proliferation and migration of monocytes and fibroblasts (64), preadipocyte proliferation and energy metabolism (84) , promotion of fibronectin matrices (85, 86) and osteoblast matrix secretion and deposition (87) . This suggests that cellular FXIII-A is involved in a range of physiological and pathological functions in addition to those for plasma FXIII discussed within this review, and that further research into the potential role of FXIII in arthritis progression, cartilage repair, bone formation and adipogenesis may be warranted. As the mechanism of activation and functional roles of plasma and cellular FXIII may be different, the use of current FXIII replacement therapies to correct defective cellular FXIII-A function also remains to be evaluated.
Summary and conclusions
FXIII concentrate (human) has supplanted cryoprecipitate and fresh frozen plasma for the treatment of patients with congenital FXIII deficiency because the latter products carry a risk for transmissible disease, and plasma transfusion may induce transfusion-related acute lung injury (88) . FXIII deficiency may also be acquired, and can be associated with severe perioperative bleeding in major surgical interventions such as in tumour, heart or orthopaedic surgery, as well as large wound surfaces such as burns, or chronic concomitant inflammatory diseases. Despite promising data from initial randomised, placebo-controlled trials (12, 16) , additional data from appropriately designed clinical trials are required to understand fully the benefits of FXIII administration for patients at risk of or suffering from perioperative bleeding. In case reports in which FXIII concentrate was used to Page 16 manage perioperative bleeding, the results of routine coagulation tests were normal (18, 20) , emphasising the need to use FXIII-specific tests in patients with unexplained perioperative bleeding.
There is an increasing body of evidence to support the view that FXIII also plays a key role in a range of physiological functions. Beyond a role in haemostasis, these functions include: 1) angiogenesis, through signalling that involves downregulation of TSP-1; 2) bacterial immobilisation, through crosslinking of bacterial surface proteins to fibrin within a plasma clot; 3) wound healing, through crosslinking of integrin components of plasma and extracellular matrix, and enhancement of cell adhesion.
While administration of FXIII concentrate may provide clinical benefits in the disease contexts described in this review, there are certain conditions in which FXIII-A may have unwanted effects.
For example, fibrin accumulation in synovial joints is thought to play a part in pathogenic pathways leading to rheumatoid arthritis (91, 92) . In these cases, the current FXIII replacement therapies available (FXIII concentrate and recombinant FXIII-A) may be detrimental rather than beneficial to patients.
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